Compare Abbott Laboratories (ABT) vs ARMOUR Residential REIT, Inc. (ARR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs ARMOUR Residential REIT, Inc. — how do they compare? Abbott Laboratories trades at $95.58 (market cap $166.94B), while ARMOUR Residential REIT, Inc. trades at $16.9 (market cap $2.11B). The key difference: Abbott Laboratories is far larger — about 79.1× ARMOUR Residential REIT, Inc.'s market cap, and ARMOUR Residential REIT, Inc. pays the higher dividend (16.96%). Which is the better fit depends on your goals.
| ABT | ARR | |
|---|---|---|
Market Cap | $166.94B | $2.11B |
Sector | Health | Financials |
52-Week High | $136.62 | $19.12 |
52-Week Low | $82.57 | $14.05 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | 16.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
ARR trades at $16.98, down 0.88% today, with a bullish technical signal from moving averages but neutral oscillators. The stock shows a low P/E of 6.9 and P/B of 0.91, with strong net income margin of 95.99% in 2025. Recent earnings beat expectations in Q1 2026, though Q3 and Q4 2025 missed. Dividend payments of $0.24 per share continue consistently, supporting income appeal amid mixed analyst sentiment.
Outlook is cautious with 60% hold ratings; consensus target is $18.50 offering ~9% upside. Risks include volatile cash flows from large investing activities and reliance on dividend sustainability. Institutional sentiment is divided, with Zacks rating it Strong Sell on June 23, 2026, contrasting with some bullish dividend coverage analyses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About ARMOUR Residential REIT, Inc.
ARMOUR Residential REIT Inc is a real estate investment trust that invests in residential mortgage-backed securities or RMBS. These are issued or guaranteed by U.S.-government-sponsored enterprises, such as Fannie Mae, Freddie Mac, or Ginnie Mae. The company's investment portfolio is composed of mortgage-backed securities, adjustable-rate mortgage securities, and multifamily mortgage-backed securities. In terms of total fair value, most Armour's investments are long-term, fixed-rate agency RMBS. Multifamily RMBS also represents a substantial amount. Fannie Mae guarantees most of the company's holdings. Armour derives substantially all its revenue as interest income from its investments.
Read more on ARR →
